Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research.The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development.
Ranbaxy views its R&D capabilities as a vital
component of its business strategy that will provide the company with a sustainable, long-term
competitive advantage.The company today has a pool of 1,100 scientists who are engaged in path- breaking research.
The Company has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe with a presence in 23 of the Top 25 pharma markets of the world. Ranbaxy has robust operations USA, UK, France, Germany, Russia, India, Brazil, China and South Africa and is strengthening its business in Japan , Italy, Spain and several other markets in Asia Pacific and Latin America. In India a strong market presence and a significant distribution network give the company an edge over its competition. A balanced geographical presence coupled with a strong product flow from a wide therapeutic range serve as the business building blocks of the
Company.
The Company's vision is to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets.
It also aspires to be amongst the Top 5 generic
Ranbaxy Brief Overview
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international
pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is ranked amongst the top ten generic companies worldwide.The Company has manufacturing operations in 8 countries with a ground presence in 49 countries and its products are available in over 125 countries.
Ranbaxy was incorporated in 1961 and went public in 1973. For the twelve months ended December 31, 2005, the Company's Global Sales were at US
$1178 Mn. Overseas markets accounted for over 75% of global sales.The Company's largest market USA with the sales of US $ 328 Mn, accounted for 28%, while Europe and BRIC (Brazil, Russia, India, China) countries contributed 17% and 29% to global sales.
124
RANBAXY
launches and acquisitions.The Company has posted good H1-2006 results with sales of US$ 604Mn, Profit before tax and extraordinary items at US$
54 Mn and Profit after Tax and minority interest at US$ 43 Mn. Post its strong H1 2006 results, the management has re-iterated its guidance of achieving 18% growth in sales in 2006.
players with US $5 Bn in sales, by 2012.Together with the commitment of a 9,000 strong
multicultural workforce, Ranbaxy continues to aggressively pursue its mission to become a Research-based International Pharmaceutical Company.
Ranbaxy Financials
Ranbaxy has witnessed a CAGR of 16% in revenues since 2002.This growth has been led by its foray in the international generics markets, primarily the USA. Its other key geographies.i.e.Europe and BRICS Countries have been the other key
contributors to growth over the past three years.
In 2005, however the revenues and profits were under pressure on account of fewer new launches and pricing pressures in the US, the Company’s key market.
The Company is targeting higher growth in the future by focusing on gaining scale and size in USA, strengthening its position in Europe, through new
125
